No-carrier-added radiosynthesis of [123I]HIPDM: N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]i odobenzyl)-1,3-propanediamine

S. M. Moerlein, G. S. Lannoye, M. J. Welch

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The multi-millicurie production of the SPECT radiopharmaceutical N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]i odobenzyl)-1,3-propanediamine ([123I]HIPDM) in high specific activity is described. Using no-carrier-added electrophilic iododeprotonation reactions and HPLC purification, [123I]HIPDM can be isolated in 70-76% radiochemical yield and specific activity >2000 Ci/mmol within an overall preparation time of 75 min. This methodology is readily adapted to the clinical setting, and eliminates the need for co-injection of macroscopic HIPDM in SPECT imaging procedures.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalInternational Journal of Radiation Applications and Instrumentation. Part
Issue number3
StatePublished - 1990


Dive into the research topics of 'No-carrier-added radiosynthesis of [123I]HIPDM: N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]i odobenzyl)-1,3-propanediamine'. Together they form a unique fingerprint.

Cite this